Study:
A Phase 2 Study of AZD2171 (Cediranib) With Modified FOLFOX6 in Patients With Advanced Biliary Cancers
Rationale:
n/a
Purpose:
This phase II trial is studying how well giving cediranib maleate together with combination
chemotherapy works in treating patients with advanced biliary cancers. Cediranib maleate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by
blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin,
leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving cediranib
maleate together with combination chemotherapy may kill more tumor cells
Study Status: Suspended
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Adult Primary Cholangiocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Localized Unresectable Adult Primary Liver Cancer
Periampullary Adenocarcinoma
Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer |
Drug: cediranib maleate
Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil |
Phase 2 |
Verified by
National Cancer Institute (NCI)
January, 2013
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01229111
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Smitha Krishnamurthi., Principal Investigator